CDEK
← All drugs Report issue

ramosetron

Small moleculeexperimental

Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting. Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women". In India it is marketed under the brand name of Ibset. — Wikipedia

Clinical trial activity

53 trials · 25 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
15
Phase 3
10
Phase 4
14

Earliest trial started Mar 1, 2005 (NCT00189813)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21
Mol. weight
279.34 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1h-benzimidazol
  • ibsetron
  • ibsetron hcl
  • ibsetron hydrochloride
  • irribow
  • methanone, (1-methyl-1h-indol-3-yl)(4,5,6,7-tetrahydro-1h-benzimidazol-5-yl)-, monohydrochloride, (r)-
  • nasea
  • ramosetron
  • ramosetron
  • ramosetron
  • ramosetron
  • ramosetron
  • ramosetron
  • ramosetron
  • ramosetron
  • ramosetron
  • ramosetron hcl
  • ramosetron hydrochloride
  • ramosetron hydrochloride
  • ym060
  • ym060
  • ym060
  • ym 060
  • ym-060

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06166615Phase 2/Phase 3 (Phase 3)Dec 15, 2023Seoul National University
NCT05577845N/AJan 1, 2023Seoul National University
NCT05326360Phase 4Dec 17, 2020Pusan National University
NCT04297293Phase 4Apr 1, 2020Seoul National University
NCT04466046N/ASep 4, 2019Daegu Catholic University
NCT03462836N/AApr 1, 2018Yonsei University
NCT03409835N/AMar 1, 2018Seoul National University
NCT03232125N/AAug 1, 2017Yonsei University
NCT03278522Phase 4Jul 1, 2017Konkuk University
NCT02869984Early Phase 1 (Phase 1)Aug 1, 2016Dong-A Pharmaceutical, Seoul National University
NCT02625181N/AJul 1, 2016University of Washington, Vanderbilt University
NCT02849483Phase 4Jul 1, 2016Kyung Hee University
NCT02604797N/AJan 1, 2016Fudan University
NCT02617121N/ANov 1, 2015Hallym University
NCT02532634Phase 4Aug 1, 2015Astellas, Catholic University of Korea, Hallym University
NCT02509143N/AJul 1, 2015Korea Institute of Oriental Medicine, Pusan National University
NCT03017222N/AJul 1, 2015Yonsei University
NCT02803788Phase 4Jul 1, 2015Government Medical College, Haldwani
NCT02478645Phase 4Jun 19, 2015Yonsei University
NCT02478047N/AJun 1, 2015National Basic Research Program, China, Tianjin University of Traditional Chinese Medicine
Showing 20 of 53 trials
Page 1 / 3

Organizations

Research & Development (25)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Seoul National UniversityAcademic/Hospital131252009
AstellasFor profit121042005
Yonsei UniversityAcademic/Hospital8822008
Hallym UniversityAcademic/Hospital4442010
Catholic University of KoreaAcademic/Hospital3232011
Kyung Hee UniversityAcademic/Hospital2212010
Kyungpook UniversityAcademic/Hospital2212014
MerckFor profit2012010
Pusan National UniversityAcademic/Hospital2222015
Chonnam National UniversityAcademic/Hospital1112012
Daegu Catholic UniversityAcademic/Hospital1112019
Dong-A PharmaceuticalFor profit1012016
Fudan UniversityAcademic/Hospital1112016
Government Medical College, HaldwaniAcademic/Hospital1112015
Ilsan HospitalAcademic/Hospital1112013
Keimyung UniversityAcademic/Hospital1112013
Konkuk UniversityAcademic/Hospital1112017
Korea Institute of Oriental MedicineAcademic/Hospital1012015
Korea UniversityAcademic/Hospital1012011
National Basic Research Program, ChinaAcademic/Hospital1012015
25 organizations
Page 1 / 2